Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|April 21, 2026
High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008-2020Jakob Nordberg Nørgaard, Kari Lenita Falck Moore, Tobias S Slørdahl, et al.
Journal of Patient-Reported Outcomes|February 5, 2024
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study GroupLene Kongsgaard Nielsen, Fredrik Schjesvold, Sören Möller, et al.
European Journal of Haematology|December 5, 2024
Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET StudyTine Rosenberg, Sören Möller, Niels Abildgaard, et al.
Future Oncology (London, England)|September 15, 2021
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM studyPaul G Richardson, Simon J Harrison, Sara Bringhen, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2024
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed TherapyFrida Bugge Askeland, Hege M Frøen, Nils Bolstad, et al.
The Lancet. Haematology|February 5, 2025
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trialFrida Bugge Askeland, Einar Haukås, Tobias S Slørdahl, et al.
Molecular Oncology|February 11, 2022
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergisticallyMariaserena Giliberto, Deepak B Thimiri Govinda Raj, Andrea Cremaschi, et al.
Bone Marrow Transplantation|November 3, 2021
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trialJava Walladbegi, Roger Henriksson, Björn Tavelin, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Pageof 8